TIS and IDEMIA Join Forces to Provide Biometric Digital Identity Solutions for Financial Institutions, Using IDEMIA’s Digital Identity Platform for Research and Development
Going forward, the two companies aim to conduct verification testing in Japan throughout 2018 targeted at financial institutions such as banks and credit card companies, amongst others, through joint research and development of highly secure and reliable biometric digital identity solutions based on IDEMIA’s digital identity and payment platform.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180531005666/en/
Biometric digital identity solutions for financial institutions are solutions that support the utilization of digital identity technologies, including biometric authentication, identity verification, and digital signatures. The incorporation of advanced digital identity technologies will enable the development of secure and convenient services for end users.
TIS has developed the brand-name of “PAYCIERGE”, based on its rich experience with development of critical systems for credit card companies and cutting-edge technologies. It has developed a broad range of services, from business systems that perform debit and prepaid card processing to mobile solutions in close proximity to the consumer for enhancing user convenience.
IDEMIA is the global leader in the fields of biometrics (fingerprint, facial and iris authentication), digital identity, and payment solutions. It has dozens of years of expertise worldwide, across the entire value chain in the field of Augmented Identity and provides numerous public and private markets with the most exhaustive digital trust suite (identity-verification technologies, risk-based authentication, Omni-channel online contracts, digital payments, etc.).
TIS and IDEMIA are now aiming to blend the two companies’ technologies to offer highly reliable and convenient mobile-based biometric digital identity solutions for financial institutions such as banks and credit card companies.
The following outline some of its uses:
- Enabling the opening of a bank account within just a few minutes from a remote location while maintaining regulatory (KYC*, AML*, etc.) compliance.
- Using facial authentication for secure access and performing highly-sensitive transactions (funds transfers and online payments).
- Enabling enrolment anytime, anywhere, and on any device in any type of financial product (loans, savings, life insurance, etc.) in a legally-compliant form.
TIS has been developing the new concept “PAYCIERGE 2.0” since 2016, which is adapted to the needs of the ever-evolving payments business market and offering the new solutions to this market. The linkage of the biometric authentication technology and services of IDEMIA with the financial industry experience and technologies acquired by TIS will increase the value of services in the consumer domain and create a variety of payment services with high levels of security and usability.
Pierre Barrial, Executive Vice-President of IDEMIA’s Financial Institutions Business Unit, made the following comments with respect to this joint research: “I am proud of our partnership with TIS. By combining IDEMIA’s best-in-class knowledge in ID integration and TIS’s outstanding IS integration, we can create superior value-added services for Japanese financial institutions, acquire new customers, speed up market entry, and reduce integration costs.”
Kiyotaka Nakamura, TIS Managing Executive Officer and Division Manager of the Payment Services Division of the Service Strategy Sector, made the following comments: “I am very happy that we were able to announce the research and development efforts with IDEMIA, the global leader in Augmented Identity. TIS has been developing “PAYCIERGE” solutions, but the importance of security and usability has become clear with recent progress in FinTech. We will see business innovation and market creation in the payments domain utilizing the experience and technologies acquired by TIS and the security technologies and high-usability solutions of IDEMIA.”
*KYC: Know Your Customer
*AML: Anti-Money Laundering
TIS retail payments solution, “PAYCIERGE”, is the comprehensive brand for retail payment solutions that provide very convenient, secure mechanisms to all customers who need to make retail payments. “PAYCIERGE 2.0” is a new concept adapted to the needs of the ever-evolving payments business market. It helps broadly with business success by incorporating reliable systems and secure operations that leverage the advanced technologies, which have an overwhelming market share in the credit card industry, and rich know-how of TIS under the theme of “connections”, which includes strengthening “connections” by making alliances, strengthening “connections” with an open API platform, and developing overseas markets.
For more details, please refer to the following URL:
TIS of TIS INTEC Group offers a variety of service-oriented IT solutions, such as data centers and cloud IT solutions in addition to SI and commissioned development. At the same time, it has a global support system centralized in the China and ASEAN region, which supports more than 3000 business partners in various industries such as finance, manufacturing, distribution/service, public sector, and communications to contribute to the growth of our customers’ businesses.
For more details, please refer to the following URL:
OT-Morpho is now IDEMIA, the global leader in Augmented Identity, with
the ambition to empower citizens and consumers alike to interact, pay,
connect, travel, and vote in ways that are now possible in a connected
Securing our identities has become mission critical in the world we live in today. By standing for Augmented Identity, we reinvent the way we think, produce, use and protect this asset, whether for individuals or for objects. We ensure privacy and trust as well as guarantee secure, authenticated and verifiable transactions for international clients from Financial, Telecom, Identity, Public Security and IoT sectors.
OT (Oberthur Technologies) and Safran Identity & Security (Morpho) have joined forces to form IDEMIA. With close to $3 billion in revenue and 14,000 employees around the world, IDEMIA serves clients in 180 countries.
HAVAS PARIS PR Agency
Corporate Planning SBU
Corporate Communication Department
Details for inquiries:
Service Strategy Secto
Payment Services Division
PAYCIERGE general contact
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Tilaa tiedotteet sähköpostiisi
Haluatko tietää asioista jo ennen kuin ne uutisoidaan? Kun tilaat tiedotteemme, saat ne sähköpostiisi yhtä aikaa suomalaisen median kanssa. Tilauksen voit halutessasi perua milloin tahansa.
Lue lisää julkaisijalta Business Wire
BioNTech Signs Collaboration Agreement with Pfizer to Develop mRNA-based Vaccines for Prevention of Influenza16.8.2018 08:00 | Tiedote
BioNTech AG, a rapidly growing biotechnology company focused on precise immunotherapies for the treatment of cancer and infectious disease, today announced that it has entered into a multi-year research and development (R&D) collaboration with Pfizer Inc. (NYSE: PFE) to develop mRNA-based vaccines for prevention of influenza (flu). Under the terms of the agreement, BioNTech and Pfizer will jointly conduct research and development activities to help advance mRNA-based flu vaccines. Pfizer will assume sole responsibility for further clinical development and commercialization of mRNA-based flu vaccines, following BioNTech’s completion of a first in human clinical study. BioNTech will receive $120 million in upfront, equity and near-term research payments and up to an additional $305 million in potential development, regulatory and commercial milestone payments. In addition, BioNTech will receive up to double-digit tiered royalty payments associated with worldwide sales if the program reac
Maxion Wheels to Showcase Market-Leading Light Weight Commercial Vehicle Wheels at REIFEN 201816.8.2018 07:05 | Tiedote
Maxion Wheels, the world’s largest producer of wheels, announced today its participation in REIFEN, the leading tire and wheel industry event in Europe, from Sept. 11 – 15, 2018 in Hall 12.1 / Stand D24. For the first time, REIFEN will be co-located with Automechanika Frankfurt at the Messe Frankfurt. “REIFEN is the premier event for European tire and wheel manufacturers and resellers, bringing us together to meet and collaborate on the important aftermarket themes of innovation, service and delivery,” stated Mark Gerardts, Vice President of Global Sales and Marketing, Maxion Wheels. “After a highly popular launch to truck and trailer OEMs in 2017, we’re excited to have the industry’s lightest mass production steel wheel now available to our aftermarket distributors. This wheel, along with several others, including our new 10.00W-20 wide base tubetype and tubeless heavy duty armored vehicles wheel are great examples of our continued efforts to bring our OE multi-application innovations
Lenovo Accelerates Turnaround with Back-to-Back, Double-Digit Quarterly Revenue Growth16.8.2018 02:40 | Tiedote
Lenovo Group (HKSE: 0992) (PINK SHEETS: LNVGY) today announced results for its first fiscal quarter ended June 30, 2018. For the second straight quarter, Lenovo achieved strong double-digit growth in revenue year-on-year. Group revenue reached US$11.91 billion, up 19% year-on-year. The company also reported strong pre-tax income during the quarter of US$113 million, an improvement of US$182 million year-on-year, as profitability improved across all businesses. In the first fiscal quarter, Lenovo’s profit attributable to equity holders grew to US$77 million, up US$149 million year-over-year. Basic earnings per share in the first fiscal quarter was 0.65 US cents or 5.10 HK cents. “As we persistently execute our 3-wave strategy, all our businesses made solid improvements in both revenue and profitability. Lenovo has passed the turning point and entered a phase of ‘acceleration’ - accelerating the execution of our transformation strategy and accelerating the rising momentum in business per
CORRECTING and REPLACING Ebola Successfully Neutralized by Latest Generation Polyclonal Immunotherapy16.8.2018 01:37 | Tiedote
Please replace the release with the following corrected version due to multiple revisions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180815005602/en/ New Ebola immunotherapy developed by SAB Biotherapeutics uses natural human polyclonal antibodies to combat disease. (Photo: SAB Biotherapeutics) The corrected release reads: EBOLA SUCCESSFULLY NEUTRALIZED BY LATEST GENERATION POLYCLONAL IMMUNOTHERAPY Promising new platform can rapidly respond to emerging infectious diseases Sioux Falls, SD, August 15, 2018 – SAB Biotherapeutics, Inc. (SAB), a clinical-stage biopharmaceutical company, today announced that its anti-Ebola immunotherapy (SAB-139) provided “100% protection against a lethal dose of the Ebola virus” in a recent animal study published in The Journal of Infectious Diseases . The study was conducted at the Integrated Research Facility, National Institute of Allergy and Infectious Diseases, National Institutes of He
QConnect – Markkinoiden älykkäin, erittäin kompakti ja lujatekoinen viestintälaite15.8.2018 23:23 | Tiedote
Quake Global, Inc. (QUAKE), yksi maailman johtavista IoT-markkinoiden toimittajista, julkaisi QConnect™, uuden sukupolven kehittyneen telematiikkalaitteen. Äärimmäisen kompakti QConnect integroituu kiinteisiin ja liikkuviin omaisuuksiin niiden seuraamiseksi, valvomiseksi ja hallitsemiseksi reaaliajassa mistä ja milloin tahansa. Laite tarjoaa useita pitkälle kehitettyjä langattomia kommunikaatiovaihtoehtoja, mukaan lukien LTE/2G/3G, kaksitaajuus-Wi-Fi, Bluetooth/BLE, V2X ja satelliitti. Laite on suunniteltu vastaamaan moniin eri vaatimuksiin yksinkertaisista ja edullisista seurantasovelluksista aina korkean suorituskyvyn monikanavaisiin videon suoratoistosovelluksiin. Tämä lehdistötiedote sisältää multimediaa. Katso koko julkaisu täällä: https://www.businesswire.com/news/home/20180815005706/fi/ Quake Global’s new QConnect, the most intelligent, global, ultra-compact and rugged communication device available (Photo: Business Wire) QConnect tarjoaa joustavuutta sen ainutlaatuisilla sovell
Ebola Successfully Neutralized by Latest Generation Polyclonal Immunotherapy15.8.2018 20:43 | Tiedote
SAB Biotherapeutics, Inc. (SAB), a clinical-stage biopharmaceutical company, today announced that its anti-Ebola immunotherapy (SAB-139) provided “100% protection against a lethal dose of the Ebola virus” in a recent animal study published in The Journal of Infectious Diseases . The study was conducted by the National Interagency Confederation for Biological Research and other collaborators including United States Army Medical Research Institute of Infectious Diseases (USAMRIID) and the Naval Medical Research Center (NMRC). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180815005602/en/ New Ebola immunotherapy developed by SAB Biotherapeutics uses natural human polyclonal antibodies to combat disease. (Photo: SAB Biotherapeutics) According to the World Health Organization, Ebola virus disease (EVD), formerly known as Ebola hemorrhagic fever, is a severe, often fatal illness in humans with an average fatality rate around 50%.
Uutishuoneessa voit lukea tiedotteitamme ja muuta julkaisemaamme materiaalia. Löydät sieltä niin yhteyshenkilöidemme tiedot kuin vapaasti julkaistavissa olevia kuvia ja videoita. Uutishuoneessa voit nähdä myös sosiaalisen median sisältöjä. Kaikki STT Infossa julkaistu materiaali on vapaasti median käytettävissä.Tutustu uutishuoneeseemme